The FDA is working to pull illegal products from the marketplace to protect public health, seeking to stop US sales of numerous products illegally marketed as diabetes treatments.
After deliberating, an FDA advisory panel voted to recommend the comprehensive and severe restrictions on Avandia (rosiglitazone) be changed.
A new study published in the Journal of the American Medical Association suggests that low levels of melatonin could increase the risk of developing type 2 diabetes.
According to a new report from the American Diabetes Association, diabetes cost Americans $245 billion in 2012, a 41 percent increase since 2007.
LifeScan, Inc. has issued a voluntary recall of its OneTouch Verio IQ glucose meters in the United States. Learn why they are recalling the meters and how to receive a replacement meter.
Insulinindependence, an organization that merged with the Diabetes Exercise and Sports Association in 2012, announced it will host the 2013 North American Conference on Diabetes and Exercise on August 16-18 in San Diego, California.
Epinex Diagnostics, Inc., a company developing a point-of-service test for glycated albumin, disclosed to the SEC it had raised funds from private investors and could raise up to $1.7 million in a private equity offering.
A new study published in the journal JAMA Internal Medicine found that patients taking GLP-1 therapy drugs, such as Januvia and Byetta, were at twice the risk of developing pancreatitis.
A new study revealed the heart drug Ranexa may reduce chest pain in individuals with type 2 diabetes, and may even have glucose-lowering potential. Learn more.
receive the latest information about glucose
meters, diabetic supplies, and product offers
right to your inbox. Get started today.